跳至主要内容
临床试验/IRCT201701172709N43
IRCT201701172709N43已完成2 期

The effect of oral quercetin supplement intake on oxidative markers , serum iron, liver enzymes and inflammatory indices in ß-thalassemia major patients,a double-blind placebo-controlled clinical trial

Vice chancellor for research, Iran University of Medical Sciences0 个研究点目标入组 84 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
84

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 30 years(—)
性别
All

入选标准

  • 18 to 30 year old male and female beta thalassemia major patients; Inclination to cooperate and signing the written informed consent; A minimum of 2 years of blood transfusion history; blood specimen collection 20 days after the last blood transfusion; Regular and peculiar iron-chelating therapy with desferrioxamine; Vitamin C supplement intake with desferrioxamine; Serum ferritin level between 2500 to 3500 ng/ml
  • Exclusion criteria:
  • Uncontrollable and life threatening complication due to due to the supplement intake; A change in type or amount of the iron chelator; Pregnancy or lactation; Splenectomy; Hepatitis infection and other metabolic or infectious diseases; Less than 80% compliance of supplement intake; Consumption of drugs that interfere with quercetin; Drinking more than 500 mg/day of beverages rich in flavonoids; Smoking or alcohol consumption

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Iran University of Medical Sciences

相似试验